Research output per year
Research output per year
Personal profile
Research interests
My focus is on myeloid development and leukemic dysregulation of self-renewal program. Current projects explore the early reprogramming of myeloid differentation by PML-RARA and RARA haploinsufficiency that result from the t(15;17) translocation associated with APL.
Fingerprint
Dive into the research topics where John Welch is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Endogenous and combination retinoids are active in myelomonocytic leukemias
di Martino, O., Niu, H., Hadwiger, G., Kuusanmaki, H., Ferris, M. A., Vu, A., Beales, J., Wagner, C., Menéndez-Gutiérrez, M. P., Ricote, M., Heckman, C. & Welch, J. S., Apr 2021, In: Haematologica. 106, 4, p. 1008-1021 14 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Impact of a 40-gene targeted panel test on physician decision making for patients with acute myeloid leukemia
Barnell, E. K., Newcomer, K. F., Skidmore, Z. L., Krysiak, K., Anderson, S. R., Wartman, L. D., Oh, S. T., Welch, J. S., Stockerl-Goldstein, K. E., Vij, R., Cashen, A. F., Pusic, I., Westervelt, P., Abboud, C. N., Ghobadi, A., Uy, G. L., Schroeder, M. A., Dipersio, J. F., Politi, M. C., Spencer, D. H. & 5 others, , Jan 2021, In: JCO Precision Oncology. 5, p. 191-203 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
Maiti, A., Rausch, C. R., Cortes, J. E., Pemmaraju, N., Daver, N. G., Ravandi, F., Garcia-Manero, G., Borthakur, G., Naqvi, K., Ohanian, M., Short, N. J., Alvarado, Y., Kadia, T. M., Takahashi, K., Yilmaz, M., Jain, N., Kornblau, S., Montalban-Bravo, G., Sasaki, K., Andreeff, M. & 15 others, , Mar 2021, In: Haematologica. 106, 3, p. 894-898 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access8 Scopus citations -
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
DiNardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G., Ohanian, M., Alvarado, Y., Issa, G. C., Montalban-Bravo, G., Short, N. J., Yilmaz, M., Bose, P., Jabbour, E. J., Takahashi, K., Burger, J. A., Garcia-Manero, G., Jain, N. & 19 others, , Oct 2020, In: The Lancet Haematology. 7, 10, p. e724-e736Research output: Contribution to journal › Article › peer-review
53 Scopus citations -
Expanding dasatinib beyond KIT in acute myeloid leukemia
Welch, J. S., Dec 2020, In: Haematologica. 105, 12, p. 2708-2710 3 p.Research output: Contribution to journal › Editorial
Open Access